GlucoFriend-evaluation the Effectiveness of Glucobay When Combined With a Basal Insulin

Combined Use of a Basal Insulin and Glucobay For Reducing PPG to End Diabetes Progress

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01248481

Enrollment

539

Registered

2010-11-25

Start date

2010-09-30

Completion date

2012-07-31

Last updated

2013-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Keywords

Acarbose/Glucobay®, Basal insulin, PPG (Postprandial Glycaemia)

Brief summary

To evaluate the effectiveness of Glucobay when combined with a basal insulin under daily-life treatment conditions in a large sample of Korean patients.

Interventions

DRUGAcarbose (Glucobay, BAYG5421)

Adult female and male patients are scheduled to be treated with acarbose will be enrolled after the therapy decision has been made. Physicians should consult the full prescribing information for Glucobay® before enrolling patients and familiarize themselves with the safety information in the product package label.

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Signed written informed consent * Age ≥ 18 years * Diagnosed of type 2 diabetes for at least 6 months prior to enrollment * Patients treated with stable dose of a basal insulin (insulin glargine or insulin detemir) at least 2 months * HbA1C≥7.5 and ≤10.0%

Exclusion criteria

Design outcomes

Primary

Measure	Time frame
Change in HbA1c	After 20 weeks

Secondary

Measure	Time frame
Duration and dose of acarbose treatment	After 20 weeks
Postprandial Blood Glucose	After 20 weeks

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026